Market closedNon-fractional
Ionis Pharmaceuticals/IONS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Ticker
IONS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Carlsbad, United States
Employees
927
Website
www.ionispharma.com
IONS Metrics
BasicAdvanced
$7.6B
Market cap
-
P/E ratio
-$2.67
EPS
0.41
Beta
-
Dividend rate
Price and volume
Market cap
$7.6B
Beta
0.41
Financial strength
Current ratio
7.373
Quick ratio
6.775
Long term debt to equity
649.099
Total debt to equity
667.434
Interest coverage (TTM)
-4.25%
Management effectiveness
Return on assets (TTM)
-8.13%
Return on equity (TTM)
-98.29%
Valuation
Price to revenue (TTM)
9.609
Price to book
25.48
Price to tangible book (TTM)
25.48
Price to free cash flow (TTM)
-21.6
Growth
Revenue change (TTM)
34.75%
Earnings per share change (TTM)
15.71%
3-year revenue growth (CAGR)
3.13%
3-year earnings per share growth (CAGR)
-8.84%
What the Analysts think about IONS
Analyst Ratings
Majority rating from 24 analysts.
IONS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$119M
-63.20%
Net income
-$143M
1,452.17%
Profit margin
-119.59%
4,125.80%
IONS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.60
-$1.03
-$0.06
-$0.98
-
Expected
-$0.90
-$1.04
-$0.83
-$1.05
-$0.94
Surprise
-33.46%
-1.05%
-92.78%
-6.78%
-
IONS News
AllArticlesVideos
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Benzinga·4 days ago
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
PRNewsWire·5 days ago
Ionis to hold second quarter 2024 financial results webcast
PRNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $7.6B as of July 26, 2024.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of July 26, 2024.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ionis Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.